BACKGROUND: The study of near-fatal asthma (NFA) may provide a means to further our understanding of fatal asthma. Studies of NFA often are derived from a single ICU rather than from a defined population. We therefore aimed to identify factors distinguishing NFA patients (cases) from those persons treated in an emergency department (ED) [ED control subjects] and in the community (community control subjects [CCs]). METHODS: This was a population-based case-control study conducted over 20 months of 45 NFA patients (age range, 5 to 50 years), 197 ED control subjects treated in an ED, and 303 CCs, all of whom were residents of Alberta. RESULTS: The age distribution was similar between NFA patients and control subjects, with the majority being < 22 years of age (NFA patients, 68.9%; ED control subjects, 71.3%; CCs, 60.7%). Those patients with NFA were significantly more likely to have received a diagnosis before 5 years of age (66.6%), compared to ED control subjects (39.6%) and CCs (28.7%). The NFA group was significantly more likely to report moderate-to-severe disease and more frequent symptoms than the other groups. Therapy with bronchodilators was used most frequently by the NFA group compared to the ED control subjects and CCs (p < 0.001), as was therapy with inhaled steroids (p < 0.001) and oral steroids (p < 0.001). NFA patients had higher scores for vulnerability and were most likely to admit to stress as an asthma trigger. All groups had high exposure to cigarette smoke and pets. CONCLUSION: NFA patients have many modifiable risk factors and many similarities to ED control subjects and CCs with asthma. General measures to improve asthma control and awareness of risks are required in all groups.
BACKGROUND: The study of near-fatal asthma (NFA) may provide a means to further our understanding of fatal asthma. Studies of NFA often are derived from a single ICU rather than from a defined population. We therefore aimed to identify factors distinguishing NFApatients (cases) from those persons treated in an emergency department (ED) [ED control subjects] and in the community (community control subjects [CCs]). METHODS: This was a population-based case-control study conducted over 20 months of 45 NFApatients (age range, 5 to 50 years), 197 ED control subjects treated in an ED, and 303 CCs, all of whom were residents of Alberta. RESULTS: The age distribution was similar between NFApatients and control subjects, with the majority being < 22 years of age (NFApatients, 68.9%; ED control subjects, 71.3%; CCs, 60.7%). Those patients with NFA were significantly more likely to have received a diagnosis before 5 years of age (66.6%), compared to ED control subjects (39.6%) and CCs (28.7%). The NFA group was significantly more likely to report moderate-to-severe disease and more frequent symptoms than the other groups. Therapy with bronchodilators was used most frequently by the NFA group compared to the ED control subjects and CCs (p < 0.001), as was therapy with inhaled steroids (p < 0.001) and oral steroids (p < 0.001). NFApatients had higher scores for vulnerability and were most likely to admit to stress as an asthma trigger. All groups had high exposure to cigarette smoke and pets. CONCLUSION:NFApatients have many modifiable risk factors and many similarities to ED control subjects and CCs with asthma. General measures to improve asthma control and awareness of risks are required in all groups.
Authors: Wendy C Moore; Eugene R Bleecker; Douglas Curran-Everett; Serpil C Erzurum; Bill T Ameredes; Leonard Bacharier; William J Calhoun; Mario Castro; Kian Fan Chung; Melissa P Clark; Raed A Dweik; Anne M Fitzpatrick; Benjamin Gaston; Mark Hew; Iftikhar Hussain; Nizar N Jarjour; Elliot Israel; Bruce D Levy; James R Murphy; Stephen P Peters; W Gerald Teague; Deborah A Meyers; William W Busse; Sally E Wenzel Journal: J Allergy Clin Immunol Date: 2007-02 Impact factor: 10.793
Authors: Mohamed S Al-Moamary; Sami A Alhaider; Abdullah A Alangari; Mohammed O Al Ghobain; Mohammed O Zeitouni; Majdy M Idrees; Abdullah F Alanazi; Adel S Al-Harbi; Abdullah A Yousef; Hassan S Alorainy; Mohamed S Al-Hajjaj Journal: Ann Thorac Med Date: 2019 Jan-Mar Impact factor: 2.219
Authors: Nancy E Lange; Supinda Bunyavanich; Judy L Silberg; Glorisa Canino; Bernard A Rosner; Juan C Celedón Journal: J Allergy Clin Immunol Date: 2010-12-30 Impact factor: 10.793
Authors: Mohamed S Al-Moamary; Sami A Alhaider; Majdy M Idrees; Mohammed O Al Ghobain; Mohammed O Zeitouni; Adel S Al-Harbi; Abdullah A Yousef; Hussain Al-Matar; Hassan S Alorainy; Mohamed S Al-Hajjaj Journal: Ann Thorac Med Date: 2016 Jan-Mar Impact factor: 2.219